Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 Bysanti ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ...

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

Today, a brief rundown of news involving Merck and Vanda Pharmaceuticals, as well as updates from Sanofi and Novo Holdings that you may have missed.

The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a stomach condition characterized by delayed gastric emptying. Vanda ...

Vanda Pharmaceuticals (NASDAQ:VNDA) is alleging that members of the U.S. FDA "have committed to delay" its request for a hearing to discuss the agency's issuing of a Complete Response Letter in ...

WASHINGTON, April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the ...

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the rejection of the biotech's stomach disorder drug last year. The FDA has ...

British drug­mak­er As­traZeneca is re­join­ing the drug in­dus­try’s ma­jor US lob­by­ing group, PhRMA, rough­ly two years af­ter quit­ting the or­ga­ni­za­tion.

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on AnaptysBio (ANAB – Research Report), with a price target of $51.00. The company’s shares closed yesterday ...